Challenges and progress in childhood tuberculosis
Guest edited by Professor Ben Marais (University of Sydney, Australia), this series of articles provides an overview of the global child tuberculosis burden and examines issues such as diagnosis, advances in treatment, and novel vaccination approaches. The series aims to address the needs of researchers, clinicians and other individuals who require up-to-date information on this topic.
Pneumonia is pleased to be still accepting submissions for this thematic series.
Featured blog: Your last breath: Raising awareness on World Pneumonia Day
Every year, pneumonia affects millions of the most vulnerable people in our society. But although the most high profile cases often involve elderly celebrities, pneumonia is one of the leading causes of death for children under five. In this blog, Prof Ger Rijkers, co-Editor-in-Chief of Pneumonia, talks about why pneumonia is such a dangerous disease and what we can do to stop it.
Aims and scope
Pneumonia is the only journal to focus exclusively on pneumonia. Publishing original research, case reports, reviews, commentaries and correspondence, Pneumonia provides an international forum for the exchange of knowledge by scientists and clinicians involved in studying the etiology and pathogenesis of pneumonia, as well as its diagnosis, epidemiology, treatment and prevention. The journal's scope extends to research on lung infections and diagnosis, inflammation and immunity, microbial pathogenesis and viral-bacterial interactions.
Cutting-edge research, insightful reviews and dedication to the community make Pneumonia an essential resource for clinicians, researchers, respirologists and allied professionals involved with infectious diseases.
Featured article: Decreased relative risk of pneumococcal pneumonia during the last decade, a nested case-control study
Streptococcus pneumoniae (SP) is one of the most common pathogens of Community-Acquired Pneumonia (CAP), but recent reports suggest that its incidence may be declining in relation to the use of the conjugate 13-valent pneumococcal vaccine in children. The authors of this study compare the result of the immunochromatographic SP urinary antigen test (SPUAT) and clinical outcomes in patients with CAP admitted in two periods of time: 2001–2002(CAP1) and 2015–2016(CAP2).
Sign up to receive article alerts
Pneumonia is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
Professor Stephen I. Pelton is Professor of Pediatrics and Epidemiology at Boston University Schools of Medicine and Public Health in Massachusetts. He is also former Director of Pediatric Infectious Diseases at Boston Medical Center (BMC) and current Coordinator of Pediatric AIDS Program. Professor Pelton is an active clinician, investigator, a member of the Boston Medical University Campus Institutional Review Board, and mentor for trainees in Pediatric Infectious Diseases. He is principal investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trials program (IMPAACT) at BMC that seeks to evaluate new strategies for prevention and treatment of HIV in children and adolescents. His laboratory is focused on vaccine-preventable diseases, especially those due to Streptococcus pneumoniae and new vaccines for prevention of respiratory tract infection due to nontypeable Haemophilus influenzae. Professor Pelton’s work has led to his recognition as a leading clinical scientist in studies of the impact of pneumococcal conjugate vaccine on invasive and respiratory tract disease in children. He has been named as one of Boston’s top Pediatric Infectious Diseases physicians by Boston Magazine for the past 5 years (2012–2017).
Professor Ger Rijkers, co-Editor-in-Chief, has studied the interaction between Streptococcus pneumoniae and the human immune system for most of his professional career. Being a biologist and medical immunologist by training, and working in hospital laboratories, his focus of research has been the cellular and molecular mechanisms of the immune response during infection and following vaccination. Special attention is given to the major risk groups: the young, the old, and the immunocompromised. He has published widely in the peer-reviewed literature, has presented at a great number of international scientific and medical conferences and has supervised many PhD students in their research. Professor Rijkers joined the Laboratory of Medical Microbiology and Immunology of the St Antonius Hospital in Nieuwegein, The Netherlands in 2006. As of 2012 he has been head of the Science Department of University College Roosevelt, Middelburg, The Netherlands.
2017 Journal Metrics
62 days to first decision for reviewed manuscripts only
62 days to first decision for all manuscripts
138 days from submission to acceptance
22 days from acceptance to publication
217 Altmetric Mentions